CombinatoRx, Incorporated Collaborator Fovea Pharmaceuticals Reports Encouraging Clinical Results with CombinatoRx-Derived Combination Drug Candidate

CAMBRIDGE, Mass.--(BUSINESS WIRE)--CombinatoRx, Incorporated (Nasdaq Global Market: CRXX) today announced that its ophthalmics collaborator, Fovea Pharmaceuticals, reported positive results from its clinical proof-of-concept trial to assess the therapeutic effect of a CombinatoRx-derived combination drug candidate, PrednisporinTM (FOV1101), in subjects with persistent allergic conjunctivitis. Based on these data, Fovea has announced its intentions to prepare further advanced trials for PrednisporinTM both in the USA and in Europe.